Launchpad Digital Health, a seed fund and accelerator for digital health based in San Francisco, announced it is leading seed round funding for Amicomed and four other companies. These companies have now begun its twelve-month in-house immersion program.
Vorsorgegelder für das Wachstum von morgen: Nach diesem Motto hat sich die Sammelstiftung NEST entschlossen, künftig direkt in Schweizer Startups zu investieren. Dazu ist sie eine Partnerschaft mit der Risikokapitalplattform investiere.ch eingegangen.
Glycemicon AG is a Swiss biotechnology company developing so called nutraceuticals for managing prediabetes, diabetes and obesity. Nutraceuticals are products naturally occurring in food sources with extra health benefits. The company will use the funds to conduct its first clinical trials.
Twenty Thirty is a Zug based startup focusing on creating a decentralized world by creating innovation centres using of Blockchain technology. The startup announced the closing of its first round for the development products and services and infrastructure for innovation Centres.
Geneva based Prexton Therapeutics develops novel therapeutic compounds for the treatment of Central Nervous System (CNS) conditions. The Series B funding will be used to finance two phase II studies of Prexton’s lead product. Prexton Therapeutics was founded 2012 as a spin-off from Merck Serono.
Apidel SA, a Geneva based pharmaceutical company, announced the completion of its third private financing round. The startup raised a significant amount of funds to accelerate and progress clinical and commercial development of its pipeline of therapeutic products.